Biotech Values

[rstor1]

+++Overlapping phase-2 and phase-3 trials --this is a very positive development!+++

I have mixed feelings about that. Are they so confident of the dosing schedule that they don't need the PII data? Seems like a risky way of going forward, and I can't help but think that it is motivated by non-science considerations - like forcing the hand of prospective partners.

Bob